In this episode, Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the key HIV studies from CROI 2024 that are influencing their clinical practice, including:

• New data surrounding long-acting ART, including:
  • The CARES study of LA CAB + RPV in a Sub-Saharan African population using a public health approach
  • The IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIV
  • The ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ART
  • Updated data from San Francisco’s Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baseline
  • Case series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV alone
• Data on comorbidities and coinfections, including:
  • A REPRIEVE proteomic analysis to elucidate mechanistic pathways of statin effects on plaque
  • The ACTG A5371 SLIM LIVER study of semaglutide for MASLD in people living with HIV
  • The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San Francisco
• Potential novel treatment options on the horizon for people living with HIV, including:
  • Phase II data on LEN + ISL dosed orally once weekly
  • Early data on other oral weekly options
  • Data on bNAbs in combination or with other ART agents

Presenters:

Joseph J. Eron, Jr., MD
Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology
Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco
San Francisco, California

Content based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.

Link to full program: 
https://bit.ly/4awdWJM

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.